A2736
Anastrozole
≥98% (HPLC), aromatase inhibitor, solid
Synonym(s):
2;2"-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1, 3-Phenylene]bis(2-methyl-propiononitrile, Arimidex, ICI-D1033, ZD1033, a,a,a′,a′-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C17H19N5
CAS Number:
Molecular Weight:
293.37
MDL number:
UNSPSC Code:
51111800
NACRES:
NA.77
Product Name
Anastrozole, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
solid
solubility
DMSO: 40 mg/mL
originator
AstraZeneca
storage temp.
room temp
SMILES string
[n]2(ncnc2)Cc1cc(cc(c1)C(C)(C)C#N)C(C)(C)C#N
InChI
1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
InChI key
YBBLVLTVTVSKRW-UHFFFAOYSA-N
Application
Anastrozole (aromatase inhibitor) has been used:
- as a positive control in DNA fragmentation (ladder) assay
- to investigate its effects along with extra virgin olive oil and its major fatty acid component (omega-9 OA) in estrogen receptor positive mammary adenocarcinoma cells
- to study its effects on viability, cell proliferation and apoptosis in Glioblastoma multiforme model in vivo
Biochem/physiol Actions
Anastrozole is a nonsteroidal aromatase inhibitor.
Anastrozole, which contains a triazole functional group, reversibly binds to the cytochrome P-450 component of aromatase. Binding interferes with the catalytic properties of aromatase, which results in inhibition of estrogen synthesis.
The aromatase enzyme converts adrenal androgens to estrogen; this enzymatic activity is the primary source of estrogen production in postmenopausal women. One treatment for estrogen receptor-positive breast cancer in postmenopausal women is through inhibition of aromatase. Anastrozole is a nonsteroidal, benzyl-triazole derivative that inhibits aromatase through competitive inhibition and is used to treat estrogen receptor-positive breast cancer. This compound is considered a third-generation, Type II aromatase inhibitor because it is more selective and less effective (if at all) on other steroidal hormones than first and second generation inhibitors.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Anastrozole
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Novel acylated steroidal glycosides from Caralluma tuberculata induce caspase-dependent apoptosis in cancer cells
Waheed A, et al.
Journal of Ethnopharmacology, 137(3), 1189-1196 (2011)
Akanksha Mehta et al.
Fertility and sterility, 100(4), 970-974 (2013-07-09)
To evaluate surgical sperm retrieval rates in adolescents with Klinefelter syndrome and testosterone replacement therapy (TRT). Case series. Academic medical center. Ten patients with Klinefelter syndrome, aged 14-22 years, treated with testosterone replacement and aromatase inhibitor therapy for a period
Yanyan Hong et al.
Steroids, 76(8), 802-806 (2011-03-23)
Aromatase is the rate-limiting enzyme in estrogen biosynthesis. As a cytochrome P450, it utilizes electrons from NADPH-cytochrome P450 reductase (CPR) to produce estrogen from androgen. Estrogen is a key factor in the promotion of hormone-dependent breast cancer growth. Aromatase inhibitors
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A2736-10MG | 04061833359723 |
| A2736-50MG | 04061832866468 |